Endocrine Testing Market By Test Type (E2 Testing, FSH Testing, hCG Hormone Testing, LH Testing, DHEAS Testing, Progesterone Testing, Testosterone Testing, TSH Testing, Prolactin Testing, Cortisol Testing, Insulin Testing, Others), By Endocrine Disorder, By Testing Technology , By End-user - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

The endocrine system is a group of glands that create and release hormones to control important bodily functions, such as metabolism, growth, reproduction etc. The endocrine system plays a vital role in prevention of several chronic and metabolic diseases. Generally, endocrine disorders are divided into two categories: diseases resulting when the glands over-produce or under-produce (hormone imbalance) and diseases sue to development of lesions in the endocrine system.

The purpose of this research study titled ‘Endocrine Testing Market - Growth, Future Prospects, and Competitive Analysis, 2017 – 2025’ is to provide investors, developers, company executives and industry participants with in-depth analysis to allow them to take strategic initiatives and decisions related to the prospects in the global endocrine testing market. This report presents and analyzes the major trends prevalent in the global endocrine testing market and the market size and forecast.

This report categorizes the global endocrine testing market in terms of test type, endocrine disorder, testing technology, end-users and geographical distribution. For the purpose of this study, the test types considered include estradiol (E2) testing, follicle stimulating hormone (FSH) testing, human chorionic gonadotropin (hCG) hormone testing, luteinizing hormone (LH) testing, dehydroepiandrosterone sulfate (DHEAS) testing, progesterone testing, testosterone testing, thyroid stimulating hormone (TSH) testing, prolactin testing, cortisol testing, insulin testing and others. The endocrine disorders studied in this report are categorized as adrenal disorders, calcium problems, glucose (islet cells) disorders, male and female gonadal problems, hypertensive and heart disorders, thyroid disorders and pituitary disorders.

Based on testing technologies, the global endocrine testing market is studied for immunoassay technology, tandem mass spectrometry, sensors technology, monoclonal and polyclonal antibody technology, clinical chemistry technology and others. This report also categorizes the global endocrine testing market by end-users such as hospitals, clinical laboratories, research and academia, and others. Market size and forecast for each mentioned segment for the period 2015-2025 is presented in the report along with respective CAGRs for the forecast duration 2017-2025.

Geographically, the global endocrine testing market is best understood by segmenting the market into five major regions and chief region level markets as follows:

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC
  • Rest of Middle East and Africa

The market size and forecast of each considered geographical market is presented for the period 2015-2025 along with CAGRs for the forecast period 2017-2025 in this study and are further cross-sectional analysis is presented in terms of test type, endocrine disorder, testing technology, end-users and constituent region/country level markets.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints and opportunities) to have a good understanding of the current and anticipated trends in the global endocrine testing market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study. Furthermore, this report concludes with profiling of key market players currently enjoying prominent position in the endocrine testing market. The key players profiled in this report are Abbott Laboratories, AB Sciex Pte Ltd., Agilent Technologies, Inc., Biomedical Technologies (Alfa Aesar), bioMérieux SA, Bio-Rad Laboratories, Inc., DiaSorin, F. Hoffmann-La Roche Ltd., Laboratory Corporation of America Holdings, Ortho-clinical Diagnostics, Quest Technology Pte Ltd., Sysmex Corporation and Teleflex Incorporated.

For the purpose of this study, the global endocrine testing market is segmented as per the following technologies:

• Immunoassay Technology
• Tandem Mass Spectrometry
• Sensors Technology
• Monoclonal and Polyclonal Antibody Technology
• Clinical Chemistry Technology
• Others

Growing prevalence of metabolic disorders, sexual dysfunction, diabetes, renal diseases and obesity has led to emergence of heightened demand for endocrine testing methods. Regular monitoring of endocrine hormones play a critical role in the management of diabetes and related complications across all demographics. There is also an increasing significance of obesity as co-morbidity in the growing prevalence of disorders of the reproductive system, strokes, cardiovascular diseases and cancer. This increase in the patient pool is expected to favor the growth of endocrine testing market. However, high costs of novel testing technologies may restrain widespread acceptance of novel tests, especially in developing countries. Among the currently available testing technologies, immunoassay technology is the largest revenue generating segment and it is anticipated that the trend shall continue during the forecast period. Technologies such as tandem mass spectrometry will witness significant traction through the forecast period as a result of their proven precision and accuracy in result delivery.

Geographically, the global endocrine testing market is cumulative to North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

North America (U.S. and Canada) is the clear leader in the global endocrine testing market, followed by Europe. Significant prevalence of obesity, chronic endocrine disorders such as diabetes and thyroid diseases, and reproductive health disorders are the key factors contributing to the dominance of North America market. Furthermore, supportive government regulations facilitating swift adoption of novel testing technologies and evolved reimbursement scenario additionally drive the North America endocrine testing market. On the other hand, huge population base and rising incidence of lifestyle-related diseases has led to the emergence of Asia Pacific as the fastest progressing regional market for endocrine testing.

The detailed regional classification of the global endocrine testing market is as follows:

• North America (U.S. & Canada)
• Europe (U.K., Germany, France, Italy, Spain and Rest of Europe)
• Asia Pacific (China, Japan, and Rest of Asia Pacific)
• Latin America (Brazil, Mexico, and Rest of Latin America)
• Middle East and Africa (GCC and Rest of Middle East and Africa)